PubMed Health⌕ Search

PubMed · 11072327

MUSCA: An Algorithm for Constrained Alignment of Multiple Data Sequences.

Abstract

Given a set of N sequences, the Multiple Sequence Alignment problem is to align these N sequences, possibly with gaps, that brings out the best commonality of the N sequences. MUSCA is a two-stage approach to the alignment problem by identifying two relatively simpler sub-problems whose solutions are used to obtain the alignment of the sequences. We first discover motifs in the N sequences and then extract an appropriate subset of compatible motifs to obtain a good alignment. The motifs of interest to us are the irredundant motifs which are only polynomial in the input size. In practice, however, the number is much smaller (sub-linear). Notice that this step aids in a direct N-wise alignment, as opposed to composing the alignments from lower order (say pairwise) alignments and the solution is also independent of the order of the input sequences; hence the algorithm works very well while dealing with a large number of sequences. The second part of the problem that deals with obtaining a good alignment is solved using a graph-theoretic approach that computes an induced subgraph satisfying certain simple constraints. We reduce a version of this problem to that of solving an instance of a set covering problem, thus offer the best possible approximate solution to the problem (provided P not equalNP). Our experimental results, while being preliminary, indicate that this approach is efficient, particularly on large numbers of long sequences, and, gives good alignments when tested on biological data such as DNA and protein sequences. We introduce the the notion of an alignment number K (2 </= K </= N), a user-controlled parameter, that lends a useful flexibility to the aligning program: this additional requirement constrains the alignment to have at least K sequences agree on a character, whenever possible, in the alignment. The usefulness of the alignment number is corroborated by the users who view this as a natural constraint while dealing with a large number of sequences.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Parida, A Floratos, I Rigoutsos. 1998. MUSCA: An Algorithm for Constrained Alignment of Multiple Data Sequences.. https://pubmed.ncbi.nlm.nih.gov/11072327/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗